title: Comparison between the short-term outcomes of bevacizumab and ziv-aflibercept in the treatment of primary diabetic macular oedema.
authors.affiliation: Ophthalmology Department, Faculty of Medicine, Alexandria University, Kafr Abdou, Roshdi, Alexandria, Egypt.
authors.forename: Mohammed
authors.initials: M
authors.lastname: Ashraf
authors.affiliation: Ophthalmology Department, Faculty of Medicine, Alexandria University, Kafr Abdou, Roshdi, Alexandria, Egypt.
authors.forename: Hassan
authors.initials: H
authors.lastname: El Kayal
authors.affiliation: Ophthalmology Department, Faculty of Medicine, Alexandria University, Kafr Abdou, Roshdi, Alexandria, Egypt.
authors.forename: Ahmed A R
authors.initials: AAR
authors.lastname: Souka
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D003930:Diabetic Retinopathy / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D011446:Prospective Studies; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage* / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor